Richard D. Gelber
0000-0001-8270-8712
Publication & Citation Trends
Publications
586 total
Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer PDF
Cited by 1,612
OpenAlex
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer PDF
Cited by 1,385
OpenAlex
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 PDF
Cited by 1,829
OpenAlex
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 PDF
Cited by 3,689
OpenAlex
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial PDF
Cited by 1,216
OpenAlex
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial PDF
Cited by 1,305
OpenAlex
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 PDF
Cited by 3,864
OpenAlex
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 PDF
Cited by 1,369
OpenAlex
Research Topics
Breast Cancer Treatment Studies
(287)
HER2/EGFR in Cancer Research
(141)
Estrogen and related hormone effects
(108)
Advanced Breast Cancer Therapies
(86)
Cancer Treatment and Pharmacology
(79)
Affiliations
Rutgers, The State University of New Jersey
Boston University
University of Southern California
Roche (Switzerland)
University of Bern